Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INO
INOVIO PHARMACEUTICALS, INC.
NASDAQ
$1.29
▲ UP 2.38% (0.03)

KEY STATISTICS

Market Cap$89.13 M
52w High$2.98
52w Low$0.56
Dividend Yield0.36%
FrequencyMonthly
P/E-1.11
Volume1.70M
Shares Out.69.09M

COMPANY

LEADERSHIP

Jacqueline E. Shea
CHIEF EXECUTIVE
Jacqueline E. Shea

COMPENSATION 2026

Salary$728,000
Stock Awards$346,101
Incentive Plan Pay$144,144
All Other Comp.$16,955
Total$1,587,155

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 8, 1998
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
112

PRICE TARGET

Target High$3.00
Target Low$2.50
Target Median$2.75
Target Consensus$2.75

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$2.27M
NOV
10
TUE

SPLIT RECORD

DATETYPERATIO
2024-01-25Reverse1:12
2014-06-06Reverse1:4
2004-09-13Reverse1:4

PRICE

$1.29 ▲ UP 2.38% (+$0.03)
OVERLAYS
$1.26$1.27$1.29$1.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.29

About Inovio Pharmaceuticals, Inc.

https://www.inovio.com ↗

Inovio Pharmaceuticals develops DNA-based medicines using SynCon and CELLECTRA technologies to treat HPV-related diseases, cancers, infectious diseases, and collaborates with global partners on various clinical and vaccine programs.

INDUSTRY

Biotechnology

A PRODUCT INOVIO PHARMACEUTICALS, INC. IS KNOWN FOR

INO-3107
INO-3107

Inovio's leading late-stage DNA immunotherapy for Recurrent Respiratory Papillomatosis (RRP) is under FDA review, marking its most advanced pipeline product and primary focus toward potential commercialization.

COMPETITORS

COMPETITOR
PGEN COMPARE

Revenue by Products

IconPRODUCTQ2-2022Q3-2022Q1-2025Q4-2025
Product and Service Other$741.34K — — —
License$36.84K — — —
License With Affiliated Entities$6.21K $7K ▲— —
Reportable Segments— — $65.34K $0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
17
LISTED HERE
5
RANKED BY POSITION SIZE
VTI
0.00% · 2.6M
IWC
0.02% · 283.8K
QQQS
0.47% · 85.4K
SILX
0.26% · 84.1K
GERM
0.52% · 5.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
53.77%
HOLDERS
191
TOP 12 OF 191 · RANKED BY POSITION SIZE
Fmr LLC
9.8M sh · $17.13M
Adage Capital Partners Gp, L.L.C.
3.4M sh · $8.02M
Vanguard Group Inc
3.3M sh · $5.77M
Janus Henderson Group Plc
3.3M sh · $5.77M
Blackrock Fund Advisors
3.2M sh · $21.97M
Boxer Capital Management, LLC
2.8M sh · $3.13M
D. E. Shaw & Co., Inc.
2.2M sh · $3.88M
Adar1 Capital Management, LLC
2.1M sh · $2.36M
Millennium Management LLC
2.0M sh · $4.62M
Blackrock Institutional Trust Company, N.A.
1.8M sh · $12.76M
Blackrock Inc.
1.7M sh · $13.79M
Stonepine Capital Management, LLC
1.3M sh · $210.18K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2020-09-08

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Humeau Laurent
Sale · 2.2K shares
2026-05-20
★
OFFICER: CHIEF MEDICAL OFFICER
Sumner Michael John
Purchase · 9.4K shares
2026-05-20
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Shea Jacqueline Elizabeth
Purchase · 123.8K shares
2026-05-20
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Shea Jacqueline Elizabeth
Purchase · 100.2K shares
2026-05-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
NEUTRAL 1
3 GRADES IN THE LAST 12 MONTHS
Jefferies BUY Piper Sandler OVERWEIGHT HC Wainwright & Co. NEUTRAL

SECTORS PEERS

PEERPRICE
AGEN$7.66COMPARE
IRD$3.69COMPARE
FATE$2.43COMPARE
ALEC$2.34COMPARE
ABOS$2.92COMPARE
SEER$1.98COMPARE
SPRO$1.20COMPARE
MCRB$5.11COMPARE